Microbiome Science at the Kidney–Vascular Interface: Why Translation to Diagnostics and Therapies Still Lags Behind

Clicks: 5
ID: 333230
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #206 of 209 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 209 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The microbiome is a recognized modifier of immunity, metabolism, and vascular and neurological biology, with licensed therapeutics for recurrent Clostridioides difficile infection and promising applications in oncology and metabolic disease. By contrast, translation of microbiome knowledge into actionable therapies for kidney disease and hypertension remains limited. This review examines barriers to translation of microbiome effects at the kidney–vascular interface, considering mechanisms, metrics, and modifiers. Mechanistic association studies implicate microbially derived uremic toxins (indoxyl sulfate, p-cresyl sulfate, phenylacetylglutamine, trimethylamine N-oxide), short-chain fatty acids, and bile acid derivatives in kidney fibrosis, vascular and neurologic dysfunction, and blood pressure deregulation, while CKD and ensuing polypharmacy remodel oral and gut microbial communities. Candidate microbiome “metrics” – taxonomic signatures, diversity indices, and metabolite panels – lack standardization, show inconsistent replication across regions and ancestries, and provide uncertain incremental value beyond established risk markers. Interventional studies applying diets, exercise, pre-, pro-, syn- and meta-biotics, sorbents, or fecal microbiota transplantation report modest improvements in surrogate outcomes (uremic solute concentrations, inflammatory markers, blood pressure), but no convincing evidence for slower kidney function decline or fewer cardiovascular events; large controlled sorbent trials have been neutral on hard kidney endpoints. This review highlights cross-cutting obstacles, including complex confounding and reverse causation, reliance on stool-only sampling, temporal instability of microbial communities, analytic heterogeneity, strict regulation of live biotherapeutics, and inequities. Priorities to enable progress from plausible biology to clinically useful tools for CKD and hypertension include harmonized multiethnic longitudinal cohorts, multi-omic integration, and mechanism-driven intervention trials.
Reference Key
openalex_W7223097828 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carmine Zoccali, Griet Glorieux, Rosella Cianci, Francesca Mallamaci, Alp Ikizler, Raymond Vanholder
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag362
URL
https://doi.org/10.1093/ckj/sfag362
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.